Search Results

Displaying Results 1-2 of 2 "'GXII'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® <em>(garadacimab-gxii)</em> in Children with Hereditary Angioedema (HAE)

Jul 27, 2026, 09:00 ET CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). ANDEMBRY is approved in over 40 countries for

More news about: CSL

Plasma Fractionation Market to Reach USD 51.06 Billion by 2032, Driven by Rising Demand for Immunoglobulins and Growing Prevalence of Immune Disorders | MarkNtel Advisors

Mar 24, 2026, 03:31 ET Plasma Fractionation Market to Reach USD 51.06 Billion by 2032, Driven by Rising Demand for Immunoglobulins and Growing Prevalence of Immune Disorders | MarkNtel Advisors

patient convenience. In June 2025, CSL achieved a significant milestone with the U.S. Food and Drug Administration approval of ANDEMBRY® (garadacimab-gxii) for the prophylactic treatment of hereditary angioedema (HAE) in patients aged 12 years and older. Notably, this therapy represents the first

More news about: MarkNtel Advisors

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.